Neurocrine Biosciences, Inc. to Post FY2025 Earnings of $6.58 Per Share, William Blair Forecasts (NASDAQ:NBIX)

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Equities research analysts at William Blair boosted their FY2025 EPS estimates for shares of Neurocrine Biosciences in a research note issued to investors on Wednesday, April 17th. William Blair analyst M. Minter now forecasts that the company will earn $6.58 per share for the year, up from their prior estimate of $5.28. The consensus estimate for Neurocrine Biosciences’ current full-year earnings is $4.84 per share.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its earnings results on Wednesday, February 7th. The company reported $1.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.13 by $0.31. Neurocrine Biosciences had a net margin of 13.23% and a return on equity of 12.85%. The business had revenue of $515.20 million for the quarter, compared to analyst estimates of $518.52 million. During the same quarter in the prior year, the business posted $0.88 EPS. The company’s revenue for the quarter was up 25.0% on a year-over-year basis.

Other research analysts have also recently issued research reports about the stock. StockNews.com upgraded shares of Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research report on Thursday, February 8th. Mizuho increased their target price on shares of Neurocrine Biosciences from $116.00 to $140.00 and gave the company a “neutral” rating in a research note on Thursday, February 8th. JPMorgan Chase & Co. increased their target price on shares of Neurocrine Biosciences from $148.00 to $158.00 and gave the company an “overweight” rating in a research note on Wednesday, March 20th. Barclays increased their target price on shares of Neurocrine Biosciences from $145.00 to $150.00 and gave the company an “overweight” rating in a research note on Tuesday, January 23rd. Finally, Wells Fargo & Company increased their target price on shares of Neurocrine Biosciences from $127.00 to $140.00 and gave the company an “equal weight” rating in a research note on Thursday, February 8th. Six research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $139.67.

Neurocrine Biosciences Stock Down 0.4 %

Shares of NASDAQ:NBIX opened at $132.00 on Friday. Neurocrine Biosciences has a fifty-two week low of $89.04 and a fifty-two week high of $148.37. The firm has a 50-day simple moving average of $136.15 and a 200 day simple moving average of $126.99. The company has a market cap of $13.14 billion, a PE ratio of 54.55 and a beta of 0.25.

Insiders Place Their Bets

In other Neurocrine Biosciences news, insider Eric Benevich sold 19,818 shares of the stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $133.36, for a total value of $2,642,928.48. Following the completion of the sale, the insider now owns 40,778 shares in the company, valued at approximately $5,438,154.08. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, insider Eric Benevich sold 19,818 shares of the stock in a transaction on Monday, April 15th. The shares were sold at an average price of $133.36, for a total transaction of $2,642,928.48. Following the transaction, the insider now owns 40,778 shares in the company, valued at approximately $5,438,154.08. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Ingrid Delaet sold 5,000 shares of the stock in a transaction on Thursday, March 21st. The stock was sold at an average price of $145.06, for a total transaction of $725,300.00. Following the transaction, the insider now owns 7,507 shares in the company, valued at approximately $1,088,965.42. The disclosure for this sale can be found here. Insiders sold a total of 196,994 shares of company stock worth $27,205,009 in the last quarter. 4.40% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of NBIX. Mather Group LLC. acquired a new position in Neurocrine Biosciences in the 1st quarter valued at $26,000. Acadian Asset Management LLC bought a new stake in Neurocrine Biosciences in the 1st quarter valued at $27,000. Headinvest LLC bought a new stake in Neurocrine Biosciences in the 3rd quarter valued at $28,000. Lindbrook Capital LLC lifted its holdings in shares of Neurocrine Biosciences by 85.0% during the 4th quarter. Lindbrook Capital LLC now owns 209 shares of the company’s stock worth $28,000 after acquiring an additional 96 shares during the period. Finally, EdgeRock Capital LLC bought a new position in shares of Neurocrine Biosciences during the 4th quarter worth about $31,000. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.